Project 3
Project 3
批准号:
10438715
负责人:
John L. Cleveland
金额:
$33.98万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-25 至 2026-05-31
关键词:
AlanineAmino AcidsBindingBiological AssayCRISPR screenCancer ModelCancer PatientCancer cell lineCarbonCell DeathCell SurvivalChemoresistanceCholesterolCisplatinClinicClinicalCollaborationsCombined Modality TherapyCysteineDataData SetDevelopmentDiseaseDisease ResistanceDrug ScreeningEnzymesEpidermal Growth Factor ReceptorEtoposideFatty AcidsGeneticGenetic EngineeringGenetic studyGenetically Engineered MouseGlucoseGlutamatesGlutamineGlycolysisGrowthHexosesHumanImmunologic SurveillanceImmunosuppressionImpairmentKnock-outLactate TransporterLeadMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMass Spectrum AnalysisMetabolicMetabolismMusNeoplasm Circulating CellsNon-Small-Cell Lung CarcinomaOleatesOncogenicOxidative PhosphorylationPharmacologyPhosphotransferasesPrimary NeoplasmProteomeProteomicsProto-Oncogene Proteins c-mycResistanceRoleStructure of parenchyma of lungSurvival RateTP53 geneTestingTherapeuticTumor TissueTumor-infiltrating immune cellsUp-RegulationXenobioticsXenograft procedurebasecancer genomicscancer therapycheckpoint therapychemotherapydruggable targeteffective therapyefficacy studyembryonic stem cellenzyme activityexperimental studygenetic approachin vivoinhibitorinorganic phosphatelipid metabolismlipidomicsloss of function mutationlung small cell carcinomametabolomemetabolomicsmouse modelmutantneoplastic cellnew therapeutic targetnovel therapeuticsoverexpressionpatient derived xenograft modelpreventpurine metabolismrelapse patientsresponseretinoblastoma tumor suppressorsafety studysafety testingstandard of caresynergismtargeted treatmenttranscription factortranscriptome sequencingtreatment strategytumortumor metabolismtumor xenograft
中文摘要
项目3摘要
小细胞肺癌代谢易损性的作用及作用机制
小细胞肺癌(SCLC)缺乏有针对性的治疗,在标准护理下总存活率只有7%
顺铂/依托泊苷化疗,免疫检查点治疗仅有10%的存活率,NCI已将
小细胞肺癌是一种顽固性恶性肿瘤。因此,迫切需要确定新的和有效的靶向治疗。
对于SCLC。在非小细胞肺癌(NSCLC)中,基因组研究导致了针对
突变的EGFR等驱动因素。不幸的是,小细胞肺癌的司机是不能下药的,那里有功能丧失
肿瘤抑制基因视网膜母细胞瘤蛋白(RB1)、p53(TP53)和p73的突变及其扩增
和/或MYC癌基因转录因子的过表达。为了识别SCLC的漏洞,我们执行了
基于无偏质量谱筛选ATP结合蛋白质组中的小细胞肺癌特异性变化
基于活性的蛋白质组谱(ABPP),并在代谢组(代谢组学和脂质组学)中使用大量的
Bank of SCLC和NSCLC细胞系、患者来源的异种移植(PDX)和原发肿瘤组织。此外,我们
用抑制新陈代谢的不同方面的化合物进行筛选。整合这些数据揭示了
小细胞肺癌的糖酵解、1-碳、嘌呤和脂肪代谢水平高度升高,
两种代谢调节剂MCT乳酸转运体(MCTI)和糖酵解酶的抑制剂治疗
PFKFB3(PFKFB3i)-触发SCLC细胞系代谢崩溃、生长停滞和细胞死亡。遗传学研究
证实了这些发现,并证实了自相矛盾的观察结果,即抑制PFKFB3会引发崩溃
氧化磷酸化(OxPhos)。鉴于这些发现,我们将评估MCT和PFKFB3在
使用已建立的(来自项目1)和新的(来自Core)的SCLC的新陈代谢、开发和维护
2)基因工程SCLC小鼠模型(GEMM)、SCLC PDX和循环SCLC异种移植(CDX)
(目标1)。这些SCLC模型还将用于测试MCTI/PFKB3i组合的安全性和有效性
作为小细胞肺癌的治疗策略,我们还将评估靶向MCT和/或PFKB3对
使用SCLC GEMM的肿瘤内免疫细胞的谱系和活性(与项目4)。此外,我们将使用
ABPP、活体示踪(含项目2)、代谢流和代谢组学研究(含核心3),以确定并随后
靶向MCTs和/或PFKFB3的丢失或抑制引起的适应性代谢变化。这些研究
将定义PFKFB3抑制损害OxPhos的机制,以及MCTI/PFKFB3i如何结合
治疗引起小细胞肺癌代谢崩溃(目标2)。重要的是,我们对配对敏感的代谢组学研究
顺铂/依托泊苷耐药的SCLC PDX支持MCTI/PFKB3i治疗代表
治疗和预防耐药疾病的机会,我们将使用这些小细胞肺癌进行测试
PDX模型和SCLC GEMM(目标3)。最后,在我们的ABPP、代谢组和脂肪组分析的指导下,我们
将使用有针对性的CRISPR筛查来识别SCLC中的新代谢漏洞,我们将验证和
使用我们的SCLC模型和ABPP、代谢流和代谢组学实验进行表征(目标4)。
英文摘要
PROJECT 3 SUMMARY
ROLES AND MECHANISMS OF ACTION OF METABOLIC VULNERABILITIES OF SCLC
Small cell lung cancer (SCLC) lacks targeted therapies, and with only 7% overall survival on standard-of-care
cisplatin/etoposide chemotherapy, and only 10% survival on immune checkpoint therapy, NCI has classified
SCLC as a recalcitrant malignancy. Thus, there is an urgent need to identify new and effective targeted therapies
for SCLC. In non-small cell lung cancer (NSCLC) genomic studies led to effective targeted therapies directed at
drivers such as mutant EGFR. Unfortunately, drivers of SCLC are undruggable, where there are loss-of-function
mutations in the tumor suppressors retinoblastoma protein (RB1), p53 (TP53) and p73, as well as amplification
and/or overexpression of MYC oncogenic transcription factors. To identify vulnerabilities for SCLC, we performed
unbiased mass spectrometry-based screens for SCLC-specific changes in the ATP-binding proteome via
activity-based proteome profiling (ABPP), and in the metabolome (metabolomics and lipidomics) using a large
bank of SCLC and NSCLC cell lines, patient-derived xenografts (PDX) and primary tumor tissue. Further, we
performed screens with compounds that inhibit different aspects of metabolism. Integrating these data revealed
SCLC has highly elevated levels of glycolysis, 1-carbon and purine and lipid metabolism, and that combined
treatment with inhibitors of two metabolic regulators – MCT lactate transporters (MCTi) and the glycolytic enzyme
PFKFB3 (PFKFB3i) – triggers SCLC cell line metabolic collapse, growth arrest and cell death. Genetic studies
validated these findings, and confirmed the paradoxical observation that PFKFB3 inhibition provokes a collapse
in oxidative phosphorylation (OxPhos). Given these findings, we will assess the roles of MCTs and PFKFB3 in
the metabolism, development and maintenance of SCLC using established (from Project 1) and new (from Core
2) genetically engineered SCLC mouse models (GEMM), SCLC PDX, and circulating SCLC xenografts (CDX)
(Aim 1). These SCLC models will also be used to test the safety and efficacy of the MCTi/PFKB3i combination
as a therapeutic strategy for SCLC, and we will also assess effects of targeting MCTs and/or PFKB3 on the
repertoire and activity of intratumoral immune cells using SCLC GEMM (with Project 4). Further, we will use
ABPP, in vivo tracing (with Project 2), metabolic flux, and metabolomics studies (with Core 3) to identify and then
target adaptive metabolic changes provoked by the loss or inhibition of MCTs and/or PFKFB3. These studies
will define the mechanism by which PFKFB3 inhibition impairs OxPhos, and how combined MCTi/PFKFB3i
treatment provokes SCLC metabolic collapse (Aim 2). Importantly, our metabolomic studies of paired sensitive
and cisplatin/etoposide-resistant SCLC PDX supports the hypothesis that MCTi/PFKB3i therapy represents an
opportunity to treat and prevent emergence of chemoresistant disease, which we will test using these SCLC
PDX models and SCLC GEMM (Aim 3). Finally, guided by our ABPP, metabolomic and lipidomic analyses, we
will use targeted CRISPR screens to identify new metabolic vulnerabilities in SCLC, which we will validate and
characterize using our SCLC models and ABPP, metabolic flux and metabolomics experiments (Aim 4).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3
-
批准号:10171101
-
项目类别:
-
资助金额:$34.5万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
Project 3
-
批准号:10676736
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10153731
-
项目类别:
-
资助金额:$55.47万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10405450
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10653834
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies
-
批准号:9904591
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2019
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10524031
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:9710619
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10064576
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10307616
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9228381
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9020250
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
2013 Polyamines Gordon Research Conference and Gordon Research Seminar
-
批准号:8528010
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2013
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8346406
-
项目类别:
-
资助金额:$47.71万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8597537
-
项目类别:
-
资助金额:$74.76万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8284008
-
项目类别:
-
资助金额:$41.09万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8239135
-
项目类别:
-
资助金额:$79.38万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8676481
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8886095
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8446311
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
海外基金